DHR · Earnings call · 2026Q3T · Full report

End-Market Demand Trends

DANAHER CORP /DE/ · 2026-10-21 · Importance 20 · Surprise 24

Management reported robust underlying demand from large pharma and biopharma, strengthening biotech activity, and sequential improvement in academic demand, which remained below historical levels. Clinical and applied end markets were healthy, while improved end-market conditions and execution supported broad segment growth. In biotechnology, customers’ activity is supported by strong commercial production and a robust pipeline of new programs. Management also cited a record number of monoclonal antibodies advancing to market, biosimilar growth, newer modalities such as antibody-drug conjugates, cell therapy, and bispecifics, and reshoring as demand drivers.